Adult systemic cat scratch disease associated with therapy for hepatitis C

por Bhatti, Zahida, Berenson, Charles S
Publicado 2007

Impaired Innate COPD Alveolar Macrophage Responses and Toll-Like Receptor-9 Polymorphisms

por Berenson, Charles S., Kruzel, Ragina L., Wrona, Catherine T., Mammen, Manoj J., Sethi, Sanjay
Publicado 2015

658. Diagnostic Testing Among Patients with Suspected Recurrent Clostridioides difficile Infection (rCDI) in ECOSPOR III a Phase 3 Clinical Trial: Implications for Clinical Practic...

por Sims, Matthew, Khanna, Sahil, Pardi, Darrell, Feuerstadt, Paul, Berenson, Charles, Wu, Henry, Wang, Elaine E, Wang, Elaine E, McGovern, Barbara, von Moltke, Lisa
Publicado 2021

Healthcare resource utilization in a phase 3 trial of SER-109 in patients with recurrent Clostridioides difficile infection

por Cohen, Stuart, Louie, Thomas, Berenson, Charles, Amin, Alpesh, Lombardi, David, Pham, Sissi, Huang, Shirley, Wang, Elaine, Hasson, Brooke, McGovern, Barbara, Von Moltke, Lisa
Publicado 2022

655. Analysis of Microbiome Diversity and Secondary Bile Acid Synthesis Following SER-109 or Placebo in Patients with First Recurrent or Multiply Recurrent Clostridioides difficile...

por Kelly, Colleen R, Kraft, Colleen S, Straub, Tim, Litcofsky, Kevin, Wortman, Jennifer R, Cohen, Stuart H, Berenson, Charles, McGovern, Barbara, Hasson, Brooke, Hot, Dina, Pardi, Darrell, Ford, Christopher, Henn, Matthew
Publicado 2023

Compartmentalization of anti-oxidant and anti-inflammatory gene expression in current and former smokers with COPD

por Sidhaye, Venkataramana K., Holbrook, Janet T., Burke, Alyce, Sudini, Kuladeep R., Sethi, Sanjay, Criner, Gerard J., Fahey, Jed W., Berenson, Charles S., Jacobs, Michael R., Thimmulappa, Rajesh, Wise, Robert A., Biswal, Shyam
Publicado 2019

19. The Impact of Investigational Purified Microbiome Therapeutic SER-109 on Health-Related Quality of Life (HRQoL) of Patients with Recurrent Clostridioides difficile Infection (r...

por Hohmann, Elizabeth, Feuerstadt, Paul, Oneto, Caterina, Berenson, Charles, Lee, Christine, Pham, Sissi, Zhu, Lei, Reese, Pat Ray, Wu, Henry, Wang, Elaine E, Wang, Elaine E, von Moltke, Lisa, Garey, Kevin W
Publicado 2021

Lack of Effect of Oral Sulforaphane Administration on Nrf2 Expression in COPD: A Randomized, Double-Blind, Placebo Controlled Trial

por Wise, Robert A., Holbrook, Janet T., Criner, Gerard, Sethi, Sanjay, Rayapudi, Sobharani, Sudini, Kuladeep R., Sugar, Elizabeth A., Burke, Alyce, Thimmulappa, Rajesh, Singh, Anju, Talalay, Paul, Fahey, Jed W., Berenson, Charles S., Jacobs, Michael R., Biswal, Shyam
Publicado 2016

Correction: Lack of Effect of Oral Sulforaphane Administration on Nrf2 Expression in COPD: A Randomized, Double-Blind, Placebo Controlled Trial

por Wise, Robert A., Holbrook, Janet T., Criner, Gerard, Sethi, Sanjay, Rayapudi, Sobharani, Sudini, Kuladeep R., Sugar, Elizabeth A., Burke, Alyce, Thimmulappa, Rajesh, Singh, Anju, Talalay, Paul, Fahey, Jed W., Berenson, Charles S., Jacobs, Michael R., Biswal, Shyam
Publicado 2017

Integrated safety analysis of phase 3 studies for investigational microbiome therapeutic, SER-109, in recurrent CDI

por Sims, Matthew, Berenson, Charles, Cohen, Stuart, Wang, Elaine, Hohmann, Elizabeth, Nathan, Richard, Odio, Alberto, Cook, Paul, Brady, Kelly, Lombardi, David, Memisoglu, Asli, De, Ananya, Hasson, Brooke, Lashner, Bret, Korman, Louis, Grimard, Doria, Gutierrez, Juan Carlos Moises, McGovern, Barbara, Moltke, Lisa Von
Publicado 2023

Assessment of Quality of Life Among Patients With Recurrent Clostridioides difficile Infection Treated with Investigational Oral Microbiome Therapeutic SER-109: Secondary Analysis...

por Garey, Kevin W., Jo, Jinhee, Gonzales-Luna, Anne J., Lapin, Brittany, Deshpande, Abhishek, Wang, Elaine, Hasson, Brooke, Pham, Sissi V., Huang, Shirley P., Reese, Pat Ray, Wu, Henry, Hohmann, Elizabeth, Feuerstadt, Paul, Oneto, Caterina, Berenson, Charles S., Lee, Christine, McGovern, Barbara, vonMoltke, Lisa
Publicado 2023

Prevalence of Comorbid Factors in Patients With Recurrent Clostridioides difficile Infection in ECOSPOR III, a Randomized Trial of an Oral Microbiota–Based Therapeutic

por Berenson, Charles S, Lashner, Bret, Korman, Louis Y, Hohmann, Elizabeth, Deshpande, Abhishek, Louie, Thomas J, Sims, Matthew, Pardi, Darrell, Kraft, Colleen S, Wang, Elaine E L, Cohen, Stuart H, Feuerstadt, Paul, Oneto, Caterina, Misra, Bharat, Pullman, John, De, Ananya, Memisoglu, Asli, Lombardi, David A, Hasson, Brooke R, McGovern, Barbara H, von Moltke, Lisa, Lee, Christine H
Publicado 2023

Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection: A Phase 3, Open-Label, Single-Arm Trial

por Sims, Matthew D., Khanna, Sahil, Feuerstadt, Paul, Louie, Thomas J., Kelly, Colleen R., Huang, Edward S., Hohmann, Elizabeth L., Wang, Elaine E. L., Oneto, Caterina, Cohen, Stuart H., Berenson, Charles S., Korman, Louis, Lee, Christine, Lashner, Bret, Kraft, Colleen S., Ramesh, Mayur, Silverman, Michael, Pardi, Darrell S., De, Ananya, Memisoglu, Asli, Lombardi, David A., Hasson, Brooke R., McGovern, Barbara H., von Moltke, Lisa
Publicado 2023